Trials
PERSUADE: triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE (NCT07440381)
Study title/design: triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE (PERSUADE) (NCT07440381) Trial NCT07440381(not yet recruiting). Estimated study start September 2026. Estimated primary and study completion August 2027. Aim To assess whether early (pre-discharge)…
read more »
CLEAR HIV Trial: Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (NCT05488431)
Study title/design: Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) (NCT05488431) Trial NCT05488431 (recruiting). Estimated primary and study completion 1 March 2028. Aim To assess the effect of bempedoic acid (BA) on safety and arterial inflammation in…
read more »
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events (NCT07474649)
Study title/design: A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events (NCT07474649) Trial NCT07474649 (not yet recruiting). Estimated study start 1 June 2026. Estimated primary completion 1 June 2028 and study completion 2 October 2028. Aim To evaluate effect of triple therapy -…
read more »
LIBerate Kids: Randomised, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep (LIB003) in Children 6 to 17 Years, With Heterozygous FH
Study title/design: Randomised, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH (LIBerate Kids) Trial NCT07102511. Not yet recruiting. Estimated primary completion 31 December 2026 and study completion 30 June 2027. Aim…
read more »
Phase 3 study to assess the effect of AZD0780 on LDL-C in patients with HeFH (AZURE-HeFH) (NCT07000136)
Study title/design: A Phase 3 Study to assess the effect of AZD0780 on LDL-C in patients with HeFH (AZURE-HeFH) (NCT07000136) Trial NCT07000136. Active. Study started 2025-06-10. Estimated primary and study completion 1 April 2027. Aim To evaluate the efficacy and safety of AZD0780 in adults with…
read more »
Phase 3 study of AZD0780 on major adverse CV events in patients with a history of ASCVD events or at high risk of a first event (AZURE-Outcomes) (NCT07000357)
Study title/design: Phase 3 study of AZD0780 on major adverse CV events in patients with a history of ASCVD events or at high risk of a first event (AZURE-Outcomes) (NCT07000357) Trial NCT07000357. Not yet recruiting. Estimated primary and study completion 26 October 2029. Aim To…
read more »
Phase 3 study to assess the effect of AZD0780 on LDL-C in patients with clinical ASCVD or at risk of a first ASCVD event (AZURE-LDL) (NCT07000123)
Study title/design: Phase 3 study to assess the effect of AZD0780 on LDL-C in patients with clinical ASCVD or at risk of a first ASCVD event (AZURE-LDL) (NCT07000123) Trial NCT07000123. Active. Study started 28 May 2025. Estimated primary and study completion 11 Jan 2027. Aim…
read more »
A study to assess the efficacy, safety and tolerability of different doses of AZD0780 in patients with dyslipidaemia (NCT06173570) (PURSUIT)
Study title/design: A study to assess the efficacy, safety and tolerability of different doses of AZD0780 in patients with dyslipidaemia (NCT06173570) (PURSUIT) Trial NCT06173570 (Completed 30 September 2024). Aim To measure the effect of different daily doses of AZD0780 on LDL-C levels and other lipid…
read more »
Phase 1 randomised, single-blind, placebo-controlled study of AZD0780 (NCT05384262)
Study title/design: Phase 1 randomised, single-blind, placebo-controlled study of AZD0780 (NCT05384262) Trial First-in-human single ascending and multiple dose study of AZD0780 (NCT05384262) (Completed). Aim To assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of AZD0780 as monotherapy, and in addition to standard of care (rosuvastatin)…
read more »
CLEAR Outcomes: Bempedoic acid effects on major CV outcomes (NCT02993406)
Study title/design: CLEAR Outcomes: Bempedoic acid effects on major CV outcomes (NCT02993406) Trial NCT02993406 (Completed). Aim To determine if bempedoic acid decreases cardiovascular (CV) events in participants with or at high risk of CV disease who are statin intolerant. Study design Phase 3 randomised, double-blind,…
read more »
CLEAR Harmony Open Label Extension: Long term safety and tolerability of bempedoic acid (NCT03067441)
Study title/design: CLEAR Harmony Open Label Extension: Long term safety and tolerability of bempedoic acid (NCT03067441) Trial NCT03067441 (Completed) Aim To determine if bempedoic acid (ETC-1002) is safe and well tolerated in patients at high cardiovascular (CV) risk with elevated LDL-C not adequately controlled by…
read more »
CLEAR Harmony: Long term safety and tolerability of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02666664)
Study title/design: CLEAR Harmony: Long term safety and tolerability of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02666664) Trial NCT02666664 (Completed). Aim To determine if bempedoic acid (ETC-1002) is safe and well tolerated in patients at high cardiovascular (CV) risk with elevated…
read more »
CLEAR Wisdom: Long term efficacy of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02991118)
Study title/design: CLEAR Wisdom: Long term efficacy of bempedoic acid in patients with hyperlipidaemia and high CV risk (NCT02991118) Trial NCT0299118 (Completed). Aim To determine if bempedoic acid (ETC-1002) is effective in patients at high cardiovascular (CV) risk with elevated LDL-C not adequately controlled by…
read more »
CLEAR Serenity: Bempedoic acid in patients with hyperlipidaemia and statin intolerance (NCT02988115)
Study title/design: CLEAR Serenity: Bempedoic acid in patients with hyperlipidaemia and statin intolerance (NCT02988115) Trial NCT02988115 (Completed). Aim To determine if bempedoic acid (ETC-1002) is effective and safe in patients with elevated LDL-C who are statin intolerant. Study design Phase 3 randomised, double-blind, placebo-controlled study…
read more »
CORALreef Outcomes: Enlicitide decanoate (MK-0616) in patients at high cardiovascular risk (NCT06008756)
Study title/design: CORALreef Outcomes: Enlicitide decanoate (MK-0616) in patients at high cardiovascular risk (NCT06008756) Trial NCT06008756/MK-0616-015 (Recruiting). Estimated primary completion: 29 November 2029. Estimated study completion: 29 November 2029. Aim To evaluate the efficacy of enlicitide decanoate (MK-0616) compared to placebo in increasing the time…
read more »
CORALreef HeFH: enlicitide decanoate (MK-0616) in adults with familial hypercholesterolaemia (CORALreef HeFH, NCT05952869)
Study title/design: CORALreef HeFH: enlicitide decanoate (MK-0616) in adults with familial hypercholesterolaemia (CORALreef HeFH, NCT05952869) Trial NCT05952869/MK-0616-017 (Active, not recruiting). Estimated primary completion: 28 April 2025. Estimated study completion: 28 April 2025. Aim To evaluate the efficacy, safety and tolerability of enlicitide decanoate (MK-0616) in…
read more »
CORALreef Lipids: Enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT059528456)
Study title/design: CORALreef Lipids: enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT059528456) Trial NCT059528456/MK-0616-013 (Active, not recruiting). Estimated primary completion: 15 August 2025. Estimated study completion: 15 August 2025. Aim To evaluate the efficacy, safety and tolerability of enlicitide decanoate (MK-0616) in lowering LDL-C in adults with…
read more »
Efficacy and safety of enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT05261126)
Study title/design: Efficacy and safety of enlicitide decanoate (MK-0616) in hypercholesterolaemia (NCT05261126) Trial NCT05261126/MK-0616-008 (Completed) Aim To assess the efficacy and safety of enlicitide decanoate (MK-0616) in lowering LDL-C in adults with hypercholesterolaemia Study design Phase 2b, randomised, double-blind, placebo-controlled study of oral MK-0616 6…
read more »
A study of VERVE-102 in patients with familial hypercholesterolaemia or premature coronary artery disease (NCT06164730)
Study title/design: A study of VERVE-102 in patients with familial hypercholesterolaemia or premature coronary artery disease (NCT06164730) Trial NCT06164730 (Recruiting) Estimated primary completion: August 2026 Estimated study completion: August 2026 Aim To evaluate the safety and pharmacodynamic profile of VERVE-102 in patients with familial hypercholesterolaemia…
read more »
Long term efficacy and safety of lerodalcibep (LIB003) in patients with HoFH, HeFH or high risk for CVD requiring further LDL-C reduction (LIBerate-OLE, NCT04798430)
Study title/design Long term efficacy and safety of lerodalcibep (LIB003) in patients with HoFH, HeFH or high risk for CVD requiring further LDL-C reduction (LIBerate-OLE, NCT04798430) Trial NCT04798430/LIB003-007 (Enrolling by invitation). Estimated primary completion: 30 July 2025. Estimated study completion: 31 December 2025. Aim To…
read more »
